[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004026341D1 - IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN - Google Patents

IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN

Info

Publication number
DE602004026341D1
DE602004026341D1 DE602004026341T DE602004026341T DE602004026341D1 DE 602004026341 D1 DE602004026341 D1 DE 602004026341D1 DE 602004026341 T DE602004026341 T DE 602004026341T DE 602004026341 T DE602004026341 T DE 602004026341T DE 602004026341 D1 DE602004026341 D1 DE 602004026341D1
Authority
DE
Germany
Prior art keywords
perk
mirrors
monitoring
immunohistochemical procedure
immunohistochemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004026341T
Other languages
English (en)
Inventor
Ian Taylor
Scott Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DE602004026341D1 publication Critical patent/DE602004026341D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004026341T 2003-11-04 2004-11-04 IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN Expired - Lifetime DE602004026341D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51749503P 2003-11-04 2003-11-04
PCT/US2004/036977 WO2005044794A2 (en) 2003-11-04 2004-11-04 Immunohistochemical methods

Publications (1)

Publication Number Publication Date
DE602004026341D1 true DE602004026341D1 (de) 2010-05-12

Family

ID=34572946

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026341T Expired - Lifetime DE602004026341D1 (de) 2003-11-04 2004-11-04 IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN

Country Status (7)

Country Link
US (1) US20070292887A1 (de)
EP (1) EP1682512B1 (de)
JP (1) JP4628365B2 (de)
CA (1) CA2544855A1 (de)
DE (1) DE602004026341D1 (de)
ES (1) ES2343840T3 (de)
WO (1) WO2005044794A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490110B1 (de) 2002-03-13 2012-06-13 Biogen Idec MA Inc. Anti-alpha v beta6 antikörper
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
JP5274458B2 (ja) * 2006-07-28 2013-08-28 ノバルティス アーゲー 黒色腫における治療応答のための早期指標としての黒色腫阻害性活性（ｍｉａ）タンパク質の使用
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
CA2693013A1 (en) * 2007-07-13 2009-01-22 Prometheus Laboratories Inc. Drug selection for lung cancer therapy using antibody-based arrays
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
CA2768013C (en) 2009-07-15 2018-08-21 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
US20150086570A1 (en) * 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN106415269B (zh) * 2014-05-08 2020-11-27 贵州美鑫达医疗科技有限公司 直接免疫组织化学测定
JP2023126996A (ja) * 2020-08-05 2023-09-13 コニカミノルタ株式会社 免疫染色方法及び免疫染色組織標本の作製方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
US6174901B1 (en) * 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
EP1427810B9 (de) * 2001-08-21 2012-04-25 Ventana Medical Systems, Inc. Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
CA2499852A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
JP2007510910A (ja) 2007-04-26
WO2005044794A2 (en) 2005-05-19
EP1682512B1 (de) 2010-03-31
EP1682512A4 (de) 2008-03-12
JP4628365B2 (ja) 2011-02-09
EP1682512A2 (de) 2006-07-26
ES2343840T3 (es) 2010-08-11
CA2544855A1 (en) 2005-05-19
WO2005044794A3 (en) 2006-09-21
US20070292887A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
DE602004015886D1 (de) Vorrichtung zur Vorhersage von Kollisionen
DE50310713D1 (de) Verfahren zur bertragung von optischen polarisationsmultipl exsignalen
DE602004018714D1 (de) Verfahren zur Bereitstellung von zweiteiligen, selbstklebenden Dentalmassen
DE602004017170D1 (de) Mit öffnungen versehene abrichtescheibe verwendendes verfahren
DE602004026341D1 (de) IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN
DE50306701D1 (de) Verfahren zur zündwinkelbestimmung
DE60324884D1 (de) Verfahren zur Parameterbestimmung für lithographische Projektion
DE602006021612D1 (de) Systeme und verfahren zur messung von glykiertem hämoglobin
DE60232117D1 (de) Verfahren zur Dickenmessung
ATE472733T1 (de) Verfahren zur beurteilung von zellulären proliferativen erkrankungen
ATE416619T1 (de) Verfahren zur dearomatisierung von molkeprotein
DE602004030405D1 (de) Verfahren zur Änderung der Einstellungen
DE60320887D1 (de) Verfahren zur Reflektanzerfassung
DE602004026412D1 (de) Vorrichtung zur verhinderung von lasteinsturz
DE10394168D2 (de) Verfahren zur Kalibrierung von 3D-Bildaufnehmern
DE60336205D1 (de) Verfahren zur Betriebsmodusnotifizierung.
DE502004009594D1 (de) Verfahren zur Übertragung von Sensordaten
DE50306938D1 (de) Verfahren zur auslösung von rückhaltemitteln
ATA10532003A (de) Vorrichtung zur reinigung von nutzfahrzeugen
DE602004007657D1 (de) Verfahren zur reinigung von n-vinylpyrrolidon
DE602004028591D1 (de) Verfahren zur durchführung von gleichgewichtsbegrenzten reaktionen
DE50307674D1 (de) Verfahren zur auslösung von rückhaltemitteln
DE602004017678D1 (de) Vorrichtung zur Verwaltung von Ressourcen
DE60328693D1 (de) Verfahren zur oxadimierung von carbonylverbindungen
DE10393639D2 (de) Verfahren zur Initialisierung von programmierbaren Systemen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER HEALTHCARE, LLC, TARRYTOWN, N.Y., US

8364 No opposition during term of opposition